Answer from: Medical Oncologist at Academic Institution
For >90% of my patients with myeloma, I agree with @Craig C. Hofmeister's succinct answer below. I discuss the MASTER trial with them, but many who were considering stopping treatment (e.g., len maintenance) anyways were already considering doing so based on other toxicities such as fatigue, fina...